Home / Companies / Mineralys Therapeutics, Inc. / 21 May 2026
Mineralys Therapeutics, Inc.: meeting of 21 May 2026
Votes reported on Form N-PX, item by item
129 Form N-PX filers reported votes at the Mineralys Therapeutics, Inc. meeting of 21 May 2026. Their records fall into 3 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.
foragainstabstain, withhold or otheramber tick: the portion cast against management
Items
DIRECTOR ELECTIONSIssuer
Director elections
3 nominees; 51.6% of reported votes for; 106 filers withheld from or voted against at least one nominee.
688 vote records from 128 filers. 58 of the 128 filers that marked the item either way voted against management.
SECTION 14A SAY-ON-PAY VOTESIssuer
Advisory vote on executive pay (say-on-pay)
1 vote records from 1 filers. No filer marked a management recommendation, so no against-management figure is reported. 1 filer reported this item without a management mark.
AUDIT-RELATEDIssuer
Audit-related items (auditor ratification)
229 vote records from 127 filers. 1 of the 127 filers that marked the item either way voted against management.
How the largest families voted
* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.
Questions
How did large funds vote at the Mineralys Therapeutics, Inc. meeting?
129 Form N-PX filers reported votes at the meeting of 21 May 2026. The family table lists each of the largest families item by item.
Is this the meeting result?
No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by Mineralys Therapeutics, Inc. on Form 8-K.
Why are director elections shown as counts only?
Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.
Every meeting on file for Mineralys Therapeutics, Inc.
Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing Mineralys Therapeutics, Inc. with a meeting date within three days of 21 May 2026. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 23 Sep 2026.